Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | WZTL-002 |
Synonyms | |
Therapy Description |
WZTL-002 is composed of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing CD28 and TLR2 co-stimulatory domains, which decrease tumor growth (Blood (2023) 142 (Supplement 1): 890). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WZTL-002 | WZTL 002WZTL002|Autologous 1928T2z CAR T-cells | WZTL-002 is composed of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing CD28 and TLR2 co-stimulatory domains, which decrease tumor growth (Blood (2023) 142 (Supplement 1): 890). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |